Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01137838

Enrollment

1810

Registered

2010-06-07

Start date

2009-10-31

Completion date

2010-10-31

Last updated

2011-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

To compare the proportion of rheumatoid arthritis (RA) patients prescribed opioids, benzodiazepines, and antidepressants before versus after starting each of the following biologics: abatacept, infliximab, etanercept, adalimumab, utilizing an administrative claims database.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* ICD 9 diagnosis RA 714.0 * Documented first biologic prescription (index prescription) for abatacept, infliximab, etanercept, or adalimumab * Continuous therapy (gap between scripts no greater than 150% days supply) for minimum 6 months from index * Prescription claims data available for 6 months before and 12 months after index biologic prescription * Continuous eligibility for 6 months before and 12 months after index biologic prescription

Exclusion criteria

* Prescription claims for another biologic during the observation period (including rituximab and anakinra) * Prescriptions not continuous for at least 6 months

Design outcomes

Primary

Measure	Time frame
Proportion of RA patients prescribed opioids, benzodiazepines, and antidepressants	0-6 months after index biologic prescription

Secondary

Measure	Time frame
Prevalence of depression and/or anxiety (ICD-9 diagnosis code)	Between 0-6 months after index biologic prescription

Outcome results